
Immutep Investor Relations Material
Latest events

AGM 2024
Immutep

Corporate Presentation
1 Jun, 2025

Q3 2025
29 Apr, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Immutep Limited
Access all reports
Immutep Limited is a clinical-stage biotechnology company, recognized for its pioneering work in developing novel immunotherapy for cancer and autoimmune diseases. The company's research and development efforts are centered on Lymphocyte Activation Gene-3 (LAG-3), a crucial cell surface molecule that plays a significant role in regulating the immune system. Immutep's portfolio includes a range of innovative immunotherapies designed to either stimulate or suppress the immune system to combat cancer or autoimmune diseases. The company is headquartered in Sydney, Australia, and its shares are listed on the Nasdaq.
Key slides for Immutep Limited


AGM 2024
Immutep Limited


Corporate Presentation
Immutep Limited
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
IMM
Country
🇦🇺 Australia